[
  {
    "ts": "2025-09-16T16:30:02+00:00",
    "headline": "Kymera initiated at Outperform on potential of lead skin drug",
    "summary": "Investing.com --Analysts initiated coverage of Kymera Therapeutics with an Outperform rating and $70 price target, citing confidence in the company’s lead experimental drug for atopic dermatitis.",
    "url": "https://finance.yahoo.com/news/kymera-initiated-outperform-potential-lead-163002861.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "723efc88-a792-35f9-a327-7fa95f7ab99d",
      "content": {
        "id": "723efc88-a792-35f9-a327-7fa95f7ab99d",
        "contentType": "STORY",
        "title": "Kymera initiated at Outperform on potential of lead skin drug",
        "description": "",
        "summary": "Investing.com --Analysts initiated coverage of Kymera Therapeutics with an Outperform rating and $70 price target, citing confidence in the company’s lead experimental drug for atopic dermatitis.",
        "pubDate": "2025-09-16T16:30:02Z",
        "displayTime": "2025-09-16T16:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kymera-initiated-outperform-potential-lead-163002861.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-initiated-outperform-potential-lead-163002861.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T15:42:35+00:00",
    "headline": "Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial. The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic […]",
    "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-regn-releases-results-154235047.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "95ce9d00-5d94-31df-8088-8d2d8ab46713",
      "content": {
        "id": "95ce9d00-5d94-31df-8088-8d2d8ab46713",
        "contentType": "STORY",
        "title": "Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial. The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic […]",
        "pubDate": "2025-09-16T15:42:35Z",
        "displayTime": "2025-09-16T15:42:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYTEe3VE6sgZxe9COOwZXw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ku0XeMdDvNCP8FVlwzrrCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-regn-releases-results-154235047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-regn-releases-results-154235047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T11:03:52+00:00",
    "headline": "Drug developer Dualitas launches $65 million funding round",
    "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
    "url": "https://ca.finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ff359b0a-1fad-3066-906a-bded53976088",
      "content": {
        "id": "ff359b0a-1fad-3066-906a-bded53976088",
        "contentType": "STORY",
        "title": "Drug developer Dualitas launches $65 million funding round",
        "description": "",
        "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
        "pubDate": "2025-09-16T11:03:52Z",
        "displayTime": "2025-09-16T11:03:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/drug-developer-dualitas-launches-65-110352501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "ROG.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-16T07:35:00+00:00",
    "headline": "Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market",
    "summary": "Senhwa Biosciences, Inc. (TPEx: 6492, \"Senhwa\") today announced its official entry into the fast-growing global immuno-oncology market. The Company's novel investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the approved PD-1 inhibitor Cemiplimab (Libtayo®), provided by Sanofi and Regeneron Pharmaceuticals, in a Phase 1/2 clinical trial for patients with microsatellite-stable colorectal cancer (MSS CRC) who are refractory to immune checkpoint inhibitors.",
    "url": "https://finance.yahoo.com/news/senhwa-biosciences-cx-5461-teams-073500185.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "359e6432-7eb1-3e6e-82b8-00360296244c",
      "content": {
        "id": "359e6432-7eb1-3e6e-82b8-00360296244c",
        "contentType": "STORY",
        "title": "Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market",
        "description": "",
        "summary": "Senhwa Biosciences, Inc. (TPEx: 6492, \"Senhwa\") today announced its official entry into the fast-growing global immuno-oncology market. The Company's novel investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the approved PD-1 inhibitor Cemiplimab (Libtayo®), provided by Sanofi and Regeneron Pharmaceuticals, in a Phase 1/2 clinical trial for patients with microsatellite-stable colorectal cancer (MSS CRC) who are refractory to immune checkpoint inhibitors.",
        "pubDate": "2025-09-16T07:35:00Z",
        "displayTime": "2025-09-16T07:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b",
          "originalWidth": 213,
          "originalHeight": 54,
          "caption": "(PRNewsfoto/Senhwa Biosciences, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KrURymcxGo45pJ8Hkbe.Uw--~B/aD01NDt3PTIxMzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b.cf.webp",
              "width": 213,
              "height": 54,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/StwOrWloE4dWKz4VTGG0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/senhwa-biosciences-cx-5461-teams-073500185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/senhwa-biosciences-cx-5461-teams-073500185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "6492.TWO"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]